Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7I9JH
|
|||
| Drug Name |
Dichloroacetate
|
|||
| Synonyms |
2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Insulin-resistant disorder [ICD-11: 5A44; ICD-10: E10-E14] | Phase 4 | [1] | |
| Pyruvate dehydrogenase complex deficiency [ICD-11: 5C53.02] | Phase 3 | [2] | ||
| Pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1] | Phase 1 | [3] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C2HCl2O2-
|
|||
| Canonical SMILES |
C(C(=O)[O-])(Cl)Cl
|
|||
| InChI |
1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1
|
|||
| InChIKey |
JXTHNDFMNIQAHM-UHFFFAOYSA-M
|
|||
| CAS Number |
CAS 13425-80-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:28240
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Pyruvate dehydrogenase kinase 1 (PDHK1) | Target Info | Inhibitor | [4] |
| KEGG Pathway | HIF-1 signaling pathway | |||
| Axon guidance | ||||
| Central carbon metabolism in cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02469337) Role of Preoperative Carbohydrates Drinks, Dichloroacetate and Exercise on Postoperative Muscle Insulin Resistance (CARBEX). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02616484) Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: (DCA/PDCD). U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT01083524) Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension. U.S. National Institutes of Health. | |||
| REF 4 | Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.